1
40 51 4 8 9 5 10 5 Hodgkin's Lymphoma - staging Hodgkin's Lymphoma - restaging Non-Hodgkin's Lymphoma Haematological Malignancy Rhabdomyosarcoma Neuroblastoma Other Tumours Neurofibromatosis Type 1 Dose consideration The European Association of Nuclear Medicine (EANM) provide a paediatric dose calculator for PET imaging in children. An example of the expected doses is demonstrated in Table 2. Doses are higher than CT or PET alone, but the additional information can have significant impact on patient management. The dose risk-utility benefit should be considered on a case-to-case basis. CT dose will rely on local scanner, scanning protocol and patient size. Paediatric PET-CT: a 10-year service review Discussion Introduction The use of F18-FDG PET-CT is widely established in adult imaging. In contrast, the experience of its use in the paediatric population is relatively limited. In 2014, a dedicated paediatric PET-CT guideline was produced by the RCR. Prior to this, various clinical guidelines existed at the national and European level for adults, which were used by extrapolation in children. This led to uncertainty and a heterogeneous use of PET-CT in this patient population. We provide an insight into the scope of paediatric FDG PET-CT scans performed at a large teaching hospital over a 10 year period. We aim to highlight current RCR and European guidelines, considerations of scan acquisition, interpretation pitfalls and radiation dose. References System Diagnosis Guidelines Oncology Hodgkin’s and non-Hodgkin’s lymphoma, equivocal stage 4 disease on other imaging, extra-medullary leukaemia, malignancy of unknown primary, soft tissue sarcoma, MIBG-ve neuroblastoma, germ cell tumours, Langerhans’ cell histocytosis, relapsed FDG +ve disease. RCR 2016 1 RCR Paeds 2014 2 EANM 2008 3 Neurology Focal epilepsy. Malignant transformation of a plexiform or subcutaneous neurofibroma in neurofibromatosis 1 RCR 2016 1 RCR Paeds 2014 2 EANM 2008 3 Infection and inflammation Pyrexia of unknown origin, vasculitis, focal infection in immunocompromised patients RCR 2016 1 EANM/SNMMI 2013 4 Table 1: Selected indications for the use of FDG PET-CT in the paediatric population as per guideline. Indications in bold are some of the most frequently requested at our institution. Full guidelines available in references. Methods Retrospective review of a prospectively maintained institutional PET- CT database for all scans performed in patients under the age of 17 at a single institution. Patient demographics, clinical indication, acquisition protocol, scan findings, follow-up and final outcome were recorded. 84 patients underwent 152 PET-CT scans over a 10 year period. Clinical demand appears to be on the increase (Fig 1). 132 (87%) scans were performed for oncological indications. Non-oncological scans were performed for a variety of indications including infection and inflammation, pyrexia of unknown origin and epilepsy (Fig 2). Results Use of FDG PET-CT in paediatrics has been slower than in adults. This may be in part be due to lack of early evidence-based guidance and concern over dose. Paediatric PET-CT is now routinely established in Hodgkin’s lymphoma where baseline and post-treatment scans have an evidence-base for PET-adaptive therapy 5 . When there is uncertainty about distant disease or recurrence on conventional imaging, PET-CT can be used to clarify and potentially alter patient treatment options. Patient dose risk should be considered on a case-by-case basis, as can be balanced by the benefit of more accurate assessment and potential impact on management. In order to achieve high-quality imaging, a dedicated paediatric protocol should be developed locally by a multi- disciplinary team including radiologists, radiographers/technicians, medical physics, paediatric oncology and anaesthetics. Number of studies per year 2008-2017 Current indications for paediatric FDG PET-CT Indications for PET- CT performed at our institution between 2008-2017 Fig 1: Breakdown of number of PET-CT studies performed per year from 2008-2017. * Values up to July 2017 - projected number of scans for 2017 in yellow. The general trend since 2013 has been a steady increase in PET-CT demand. No paediatric scans were performed in Leeds in 2008/09 as a fixed PET-CT scanner was not in place until 2010. Patients referred to London. 6 6 8 Pyrexia of Unknown Origin Epilepsy Systemic/Infective Non - Oncological Oncological Interpretation pitfalls The utility of PET-CT Fig 3: CECT neck showed a left-sided necrotic lymph node in suspected lymphoma recurrence. PET-CT (axial fused at the same level as CT) and PET MIP confirm left sided recurrence as well as occult contralateral nodal disease. This finding altered planned patient management. Fig 4: 5 year old child with persistently raised inflammatory markers and systemic symptoms. PET MIP (left) and fused axial PET-CT (right top) demonstrated abnormal FDG uptake in the right thigh mass suspicious for malignancy. MRI of right thigh (right - middle and bottom) and biopsy confirmed rhabdomyosarcoma. PET-CT is typically reserved for primary staging of malignancy and problem solving. Due to high FDG uptake in a variety of tumour types and being a whole body imaging technique, PET- CT can detect local and distant disease. This makes it ideal for staging, response assessment and recurrence detection (Fig 3). It can also detection occult inflammatory or malignant pathology when clinical assessment, blood tests and conventional imaging have not found an underlying cause (Fig 4). Pitfalls in adult PET-CT are well documented but there are some specific finding more commonly encountered in paediatric patients. Physiological brown fat activity can simulate disease or potentially mask disease in neck and mediastinum (Fig 5). In post-chemotherapy patients, thymic enlargement and increased FDG activity can make response assessment difficult, especially in lymphoma patients. This is termed ‘thymic rebound hyperplasia’ and can persist up to 2 years following treatment. It should not be mistaken for active disease and can be recognised by the typical ‘inverted V shape’ on coronal imaging (Fig 6). G Chambers, R Frood, H Nejadhamzeeigilani, C Patel Department of Radiology St James Hospital, Leeds Teaching Hospital Trust, UK Weight (Kg) 10 19 32 55 70 Approximate Age (years) 1 5 10 15 Adult FDG administered activity (MBq) 38 65 102 163 196 Effective dose (mSv) 3.6 3.3 3.8 4.0 3.7 Table 2: Injected activity and effective dose for different weights of paediatric patients as defined by the EANM 0 5 10 15 20 25 30 35 Number of studies Year In order to optimise scan acquisition in paediatric patients, some modification of scanning protocol is required. Below are key considerations in our local paediatric protocol: General anaesthetic: <5 years most patients; 6-9 years case by case basis; 10+ years not routinely required. This will require assistance from a regular paediatric anaesthetist. Propanolol use: Patients 10+ years of age should ideally have propanolol premedication (in the absence of contraindications) prior to the study to suppress brown fat activity. Local protocol should be agreed with paediatric oncologists. Injected activity: Based on bodyweight (see dose considerations box) and adjusting bed position timing to ensure the patient can tolerate the entire scan Other: The scan room can be an intimidating place for young children and the use of a play therapist should be considered. A pre-scan visit to the department and scanner room can reduce anxiety for the child and parents. The injection and scan rooms should be kept warm, especially in winter, in order to minimise brown fat activity. Optimising scan acquisition and quality * 1 – Royal College of Physicians of London, Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians of Edinburgh, Royal College of Radiologists, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee. Evidence-based indications for the use of PET-CT in the United Kingdom 2016. London: The Royal College of Radiologists, 2016. 2 – The Royal College of Radiologists. Guidelines for the use of PET-CT in children. Second Ed. London: The Royal College of Radiologists, 2014. 3 – Strauss J, Franzius C, Pluger T, et al. Guidelines for 18f-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008; 35(8):1581-88. 4 – Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013; 54(4):647-58. 5 – Cheson B, Fisher R, Barrington S, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-hodgkin Lymphoma: The Lugano Classification. J Clin Onc 2014; 32(27):3059-67. n 40 51 4 8 9 5 10 5 Fig 6: Post-chemotherapy PET-CT in a Hodgkin’s lymphoma patient demonstrating increased uptake in the anterior mediastinum, which localises to an enlarged thymus. This is in keeping with thymic rebound hyperplasia and should not be confused with active disease. Fig 5: Post-chemotherapy PET-CT imaging for lymphoma demonstrates multifocal uptake in the neck and axillae, which localises to the normal appearing fat on CT. This is in keeping with physiological brown fat activity and should not be confused with nodal disease.

1 4 Current indications for paediatric FDG PET Paediatric · 40 51 4 8 9 5 10 5 Hodgkin's Lymphoma - staging Hodgkin's Lymphoma - restaging Non-Hodgkin's Lymphoma Haematological Malignancy

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: 1 4 Current indications for paediatric FDG PET Paediatric · 40 51 4 8 9 5 10 5 Hodgkin's Lymphoma - staging Hodgkin's Lymphoma - restaging Non-Hodgkin's Lymphoma Haematological Malignancy

40

51

48

9

5

10

5

Ho

dg

kin

's L

ym

ph

om

a -

sta

gin

g

Ho

dg

kin

's L

ym

ph

om

a -

re

sta

gin

g

No

n-H

od

gkin

's L

ym

ph

om

a

Ha

em

ato

log

ica

l M

alig

na

nc

y

Rh

ab

do

myo

sarc

om

a

Ne

uro

bla

sto

ma

Oth

er

Tum

ou

rs

Ne

uro

fib

rom

ato

sis

Typ

e 1

Do

se c

on

sid

era

tio

nT

he E

uro

pean A

ssocia

tion o

f N

ucle

ar

Medic

ine (

EA

NM

) pro

vid

e a

paedia

tric

dose c

alc

ula

tor

for

PE

T im

agin

g in c

hild

ren. A

n e

xam

ple

of

the e

xpecte

d d

oses is d

em

onstr

ate

d in T

able

2.

Doses a

re h

igher

than C

T o

r P

ET

alo

ne,

but th

e a

dditio

nal

info

rmation c

an h

ave s

ignific

ant

impact

on p

atient

managem

ent.

The

dose r

isk-u

tilit

y b

enefit

should

be c

onsid

ere

d o

n a

case

-to-c

ase b

asis

.

CT

dose w

ill r

ely

on local scanner,

scannin

g p

roto

col and p

atient

siz

e.

Paed

iatr

icP

ET

-CT:

a 1

0-y

ear

serv

ice r

evie

w

Dis

cu

ssio

n

Intr

od

ucti

on

The

use o

f F

18

-FD

G P

ET

-CT

is w

ide

ly e

sta

blis

hed in a

dult im

agin

g.

In c

ontr

ast, th

e e

xperi

ence o

f its u

se in th

e p

aed

iatr

ic p

op

ula

tion is

rela

tively

lim

ited

. In

20

14,

a d

edic

ate

d p

aedia

tric

PE

T-C

T g

uid

elin

e

was p

roduced b

y t

he

RC

R.

Prio

r to

this

, vario

us c

linic

al guid

elin

es

exis

ted

at

the

natio

nal and

Euro

pean

le

vel fo

r ad

ults, w

hic

h w

ere

used b

y e

xtr

apo

latio

n in

child

ren

. T

his

le

d to

un

ce

rtain

ty a

nd

a

hete

rogen

eou

s u

se o

f P

ET

-CT

in

this

patient

pop

ula

tion.

We p

rovid

e a

n in

sig

ht in

to t

he s

cope

of

pae

dia

tric

FD

G P

ET

-CT

scans p

erf

orm

ed a

t a

la

rge

tea

ch

ing h

ospital over

a 1

0 y

ear

peri

od.

We a

im t

o h

ighlig

ht curr

ent

RC

R a

nd

Euro

pea

n g

uid

elin

es,

co

nsid

era

tio

ns o

f scan a

cq

uis

itio

n,

inte

rpre

tatio

n p

itfa

lls a

nd

rad

iatio

n d

ose.

Re

fere

nc

es

Sy

ste

mD

iag

no

sis

Gu

ide

lin

es

On

co

log

yH

od

gk

in’s

an

d n

on

-Ho

dg

kin

’s ly

mp

ho

ma

,

eq

uiv

oc

al st

ag

e 4

dis

ea

se o

n o

the

r im

ag

ing

,

extr

a-m

ed

ulla

ry le

uka

em

ia, m

alig

na

nc

y o

f

un

kn

ow

n p

rim

ary

, so

fttiss

ue

sa

rco

ma

, M

IBG

-ve

ne

uro

bla

sto

ma

, g

erm

ce

ll tu

mo

urs

, La

ng

erh

an

s’

ce

ll h

isto

cyto

sis,

re

lap

sed

FD

G +

ve

dis

ea

se.

RC

R 2

016

1

RC

R P

ae

ds

2014

2

EA

NM

2008

3

Ne

uro

log

yFo

ca

l e

pile

psy

. M

alig

na

nt

tra

nsf

orm

atio

n o

f a

ple

xifo

rm o

r su

bc

uta

ne

ou

s n

eu

rofib

rom

a in

ne

uro

fib

rom

ato

sis

1

RC

R 2

016

1

RC

R P

ae

ds

2014

2

EA

NM

2008

3

Infe

ctio

n a

nd

infla

mm

atio

n

Py

rexia

of u

nk

no

wn

orig

in,v

asc

ulit

is, fo

ca

l

infe

ctio

n in

imm

un

oc

om

pro

mis

ed

pa

tie

nts

RC

R 2

016

1

EA

NM

/SN

MM

I

2013

4

Tab

le 1

: S

ele

cte

d i

nd

icati

on

s f

or

the u

se o

f F

DG

PE

T-C

T in

th

e p

aed

iatr

ic p

op

ula

tio

n a

s p

er

gu

idelin

e.

Ind

icati

on

s

in b

old

are

so

me o

f th

e m

ost

freq

uen

tly r

eq

ueste

d a

t o

ur

insti

tuti

on

. F

ull g

uid

elin

es a

vailab

le i

n r

efe

ren

ces.

Me

tho

ds

Retr

osp

ective r

evie

w o

f a

pro

sp

ectively

main

tain

ed

in

stitu

tio

nal P

ET

-

CT

data

ba

se

for

all

sca

ns p

erf

orm

ed in

patie

nts

un

der

the

ag

e o

f 17 a

t

a s

ingle

in

stitu

tio

n. P

atient

de

mogra

phic

s,

clin

ical in

dic

atio

n, acqu

isitio

n

pro

tocol, s

ca

n fin

din

gs, fo

llow

-up a

nd

fin

al outc

om

e w

ere

record

ed.

84

patie

nts

un

derw

ent

15

2 P

ET

-CT

scans o

ver

a 1

0 y

ear

peri

od.

Clin

ica

l dem

and a

pp

ears

to b

e o

n th

e in

cre

ase (

Fig

1).

132

(87%

)

scans w

ere

perf

orm

ed f

or

oncolo

gic

al in

dic

atio

ns. N

on

-oncolo

gic

al

scans w

ere

perf

orm

ed f

or

a v

ari

ety

of in

dic

atio

ns in

clu

din

g infe

ctio

n

and

in

fla

mm

ation,

pyre

xia

of u

nknow

n o

rigin

and e

pile

psy (

Fig

2).

Resu

lts

Use o

f F

DG

PE

T-C

T in p

aedia

tric

s h

as b

een s

low

er

than in a

dults. T

his

may b

e in p

art

be d

ue t

o lack o

f early e

vid

ence

-based g

uid

ance

and c

oncern

over

dose.

Paedia

tric

PE

T-C

T is n

ow

routinely

esta

blis

hed in H

odgkin

’s lym

phom

a w

here

baselin

eand p

ost-

treatm

ent

scans h

ave a

n e

vid

ence-b

ase f

or

PE

T-a

daptive t

hera

py

5.

When t

here

is u

ncert

ain

ty a

bout

dis

tant

dis

ease o

r re

curr

ence o

n

conventional im

agin

g,

PE

T-C

T c

an b

e u

sed t

o c

larify

and p

ote

ntially

alter

patient

treatm

ent options.

Patient

dose r

isk s

hould

be

consid

ere

d o

n a

case-b

y-c

ase b

asis

, as c

an b

e b

ala

nced b

y t

he b

enefit

of

more

accura

te a

ssessm

ent

and p

ote

ntial im

pact

on

managem

ent.

In o

rder

to a

chie

ve h

igh

-qualit

y im

agin

g,

a d

edic

ate

d p

aedia

tric

pro

tocol should

be d

evelo

ped locally

by a

multi-

dis

cip

linary

team

inclu

din

g r

adio

logis

ts,

radio

gra

phers

/technic

ians,

medic

al physic

s,

paedia

tric

oncolo

gy a

nd a

naesth

etics.

Nu

mb

er

of

stu

die

s p

er

ye

ar

20

08

-2017

Cu

rren

t in

dic

ati

on

s f

or

paed

iatr

ic F

DG

PE

T-C

TIn

dic

ati

on

s f

or

PE

T-

CT

perf

orm

ed

at

ou

r

insti

tuti

on

betw

een

2008-2

017

Fig

1: B

rea

kd

ow

n o

f n

um

be

r o

f P

ET-

CT

stu

die

s p

erf

orm

ed

pe

r ye

ar

fro

m 2

00

8-2

017

. *

Va

lue

s u

p

to J

uly

20

17

-p

roje

cte

d n

um

be

r o

f sc

an

s fo

r 2

01

7 in

ye

llow

. Th

e g

en

era

l tr

en

d s

inc

e 2

01

3 h

as

be

en

a s

tea

dy in

cre

ase

in

PET-

CT

de

ma

nd

. † N

o p

ae

dia

tric

sc

an

s w

ere

pe

rfo

rme

d in

Le

ed

s in

20

08

/09

as

a f

ixe

d P

ET-

CT

sca

nn

er

wa

s n

ot

in p

lac

e u

ntil 2

01

0. P

atie

nts

re

ferr

ed

to

Lo

nd

on

.

6

6

8

Pyre

xia

of

Un

kn

ow

n O

rig

in

Ep

ilep

sy

Syst

em

ic/I

nfe

ctive

No

n -

On

co

log

ica

l

On

co

log

ica

l

Inte

rpre

tati

on

pit

falls

Th

e u

tili

ty o

f P

ET

-CT

Fig

3:

CE

CT

neck s

ho

wed

a left

-sid

ed

necro

tic

lym

ph

no

de i

n s

usp

ecte

d l

ym

ph

om

a

recu

rren

ce.

PE

T-C

T (

axia

l fu

sed

at

the s

am

e

level

as C

T)

an

d P

ET

MIP

co

nfi

rm l

eft

sid

ed

recu

rren

ce a

s w

ell a

s o

ccu

lt c

on

trala

tera

l n

od

al

dis

ease.

Th

is f

ind

ing

alt

ere

d p

lan

ned

pati

en

t

man

ag

em

en

t.

Fig

4:

5 y

ear

old

ch

ild

wit

h p

ers

iste

ntl

y r

ais

ed

infl

am

mato

ry m

ark

ers

an

d s

yste

mic

sym

pto

ms

. P

ET

MIP

(left

) an

d f

used

axia

l P

ET

-CT

(ri

gh

t –

top

) d

em

on

str

ate

d

ab

no

rmal

FD

G u

pta

ke i

n t

he r

igh

t th

igh

mass s

usp

icio

us

for

malig

nan

cy.

MR

I o

f ri

gh

t th

igh

(ri

gh

t -

mid

dle

an

d

bo

tto

m)

an

d b

iop

sy c

on

firm

ed

rh

ab

do

myo

sa

rco

ma

.

PE

T-C

T is t

ypic

ally

reserv

ed f

or

prim

ary

sta

gin

g o

f m

alig

nancy a

nd

pro

ble

m s

olv

ing.

Due t

o

hig

h F

DG

upta

ke in a

variety

of

tum

our

types

and b

ein

g a

whole

body

imagin

g t

echniq

ue,

PE

T-

CT

can d

ete

ct

local and

dis

tant

dis

ease. T

his

makes it

ideal fo

r sta

gin

g,

response a

ssessm

ent

and

recurr

ence d

ete

ction

(Fig

3).

It c

an a

lso d

ete

ction o

ccult

inflam

mato

ry o

r m

alig

nant

path

olo

gy w

hen c

linic

al

assessm

ent,

blo

od t

ests

and c

onventional im

agin

g

have n

ot fo

und a

n

underlyin

g c

ause

(Fig

4).

Pitfa

lls in a

dult P

ET

-CT

are

well

docum

ente

d b

ut

there

are

som

e s

pecific

findin

g m

ore

com

monly

encounte

red in

paedia

tric

patients

. P

hysio

logic

al bro

wn

fat activity c

an s

imula

te d

isease o

r

pote

ntially

mask d

isease in n

eck a

nd

media

stinum

(F

ig 5

).

In p

ost-

chem

oth

era

py p

atients

, th

ym

ic

enla

rgem

ent

and incre

ased F

DG

activity

can m

ake r

esponse a

ssessm

ent

difficult,

especia

lly in lym

phom

a p

atients

. T

his

is

term

ed ‘th

ym

ic r

ebound h

yperp

lasia

’ and

can p

ers

ist

up t

o 2

years

follo

win

g

treatm

ent.

It should

not be m

ista

ken f

or

active d

isease a

nd c

an b

e r

ecognis

ed b

y

the t

ypic

al ‘in

vert

ed V

shape’ on c

oro

nal

imagin

g (

Fig

6).

G C

ham

bers

, R

Fro

od, H

Neja

dham

zeeig

ilani, C

Pate

l

Depart

ment

of

Radio

logy

St Jam

es H

ospital, L

eeds T

eachin

g H

ospital T

rust,

UK

We

igh

t(K

g)

10

19

32

55

70

Ap

pro

xim

ate

Ag

e

(ye

ars

)

15

10

15

Ad

ult

FD

G a

dm

inis

tere

d

ac

tiv

ity (

MB

q)

38

65

102

163

196

Eff

ec

tiv

e d

ose

(m

Sv

)3.6

3.3

3.8

4.0

3.7

Tab

le 2

: In

jecte

d a

cti

vit

y a

nd

eff

ecti

ve d

ose f

or

dif

fere

nt

weig

hts

of

paed

iatr

ic p

ati

en

ts a

s d

efi

ned

by

the E

AN

M

05

10

15

20

25

30

35

Number of studies

Ye

ar

In o

rder

to o

ptim

ise s

can a

cquis

itio

n in p

aedia

tric

patients

, som

e m

odific

ation o

f scannin

g

pro

tocol is

required.

Belo

w a

re k

ey c

onsid

era

tions in o

ur

local paedia

tric

pro

tocol:

Gen

era

l an

aesth

eti

c:

<5 y

ears

–m

ost patients

; 6

-9 y

ears

–case b

y c

ase b

asis

; 10+

years

–not ro

utinely

required. T

his

will

require a

ssis

tance f

rom

a r

egula

r paedia

tric

anaesth

etist.

Pro

pan

olo

l u

se:

Patients

10+

years

of

age s

hould

ideally

have p

ropanolo

l pre

medic

ation

(in t

he a

bsence o

f contr

ain

dic

ations)

prior

to the s

tudy t

o s

uppre

ss b

row

n f

at activity.

Local

pro

tocol should

be a

gre

ed w

ith p

aedia

tric

oncolo

gis

ts.

Inje

cte

d a

cti

vit

y:

Based o

n b

odyw

eig

ht

(see d

ose c

onsid

era

tions b

ox)

and a

dju

sting b

ed

positio

n t

imin

g t

o e

nsure

the p

atient

can t

ole

rate

the e

ntire

scan

Oth

er:

The s

can r

oom

can b

e a

n intim

idating p

lace f

or

young c

hild

ren a

nd t

he u

se o

f a p

lay

thera

pis

t should

be c

onsid

ere

d. A

pre

-scan v

isit t

o t

he d

epart

ment

and s

canner

room

can

reduce a

nxie

ty f

or

the c

hild

and p

are

nts

. T

he inje

ction a

nd s

can r

oom

s s

hould

be k

ept

warm

, especia

lly in w

inte

r, in o

rder

to m

inim

ise b

row

n f

at activity.

Op

tim

isin

g s

can

acq

uis

itio

n a

nd

qu

ality

*

1 –

Ro

ya

l Co

lleg

e o

f P

hysi

cia

ns

of

Lon

do

n, R

oya

l Co

lleg

e o

f P

hysi

cia

ns

an

d S

urg

eo

ns

of

Gla

sgo

w, R

oya

l Co

lleg

e o

f P

hysi

cia

ns

of

Ed

inb

urg

h, R

oya

l Co

lleg

e o

f R

ad

iolo

gis

ts,

British

Nu

cle

ar

Me

dic

ine

So

cie

ty, A

dm

inis

tra

tio

n o

f R

ad

ioa

ctiv

e S

ub

sta

nc

es

Ad

vis

ory

Co

mm

itte

e.

Ev

ide

nc

e-b

ase

d in

dic

atio

ns

for

the

use

of

PET-

CT

in t

he

Un

ite

d K

ing

do

m

20

16

. Lo

nd

on

: Th

e R

oya

l Co

lleg

e o

f R

ad

iolo

gis

ts, 2

01

6.

2 –

The

Ro

ya

l Co

lleg

e o

f R

ad

iolo

gis

ts. G

uid

elin

es

for

the

use

of

PET-

CT

in c

hild

ren

. Se

co

nd

Ed

. Lo

nd

on

: Th

e R

oya

l Co

lleg

e o

f R

ad

iolo

gis

ts, 2

01

4.

3 –

Str

au

ss J

, Fra

nzi

us

C,

Plu

ge

r T,

et

al.

Gu

ide

line

s fo

r 1

8f-

FD

G P

ET

an

d P

ET-

CT

ima

gin

g in

pa

ed

iatr

ic o

nc

olo

gy. Eu

r J

Nu

cl M

ed

Mo

l Im

ag

ing

. 2

00

8; 3

5(8

):1

58

1-8

8.

4 –

Jam

ar

F, B

usc

om

be

J,

Ch

iti A

, e

t a

l. EA

NM

/SN

MM

I g

uid

elin

e f

or

18

F-F

DG

use

in

infla

mm

atio

n a

nd

in

fec

tio

n. J

Nu

cl M

ed

. 2

01

3; 5

4(4

):6

47

-58

.5

–C

he

son

B, Fis

he

r R

, B

arr

ing

ton

S, e

t a

l. R

ec

om

me

nd

atio

ns

for

initia

l ev

alu

atio

n, st

ag

ing

, a

nd

re

spo

nse

ass

ess

me

nt

of

Ho

dg

kin

an

d N

on

-ho

dg

kin

Lym

ph

om

a: Th

e L

ug

an

o

Cla

ssific

atio

n. J

Clin

On

c2

01

4; 3

2(2

7):

30

59

-67

.

n 40

51 4 8 9 5 10 5

Fig

6:

Po

st-

ch

em

oth

era

py P

ET

-CT

in

a H

od

gkin

’s

lym

ph

om

a p

ati

en

t d

em

on

str

ati

ng

in

cre

ased

up

take i

n t

he a

nte

rio

r m

ed

iasti

nu

m,

wh

ich

localises t

o a

n e

nla

rged

th

ym

us.

Th

is i

s i

n

keep

ing

wit

h t

hym

ic r

eb

ou

nd

hyp

erp

lasia

an

d

sh

ou

ld n

ot

be c

on

fused

wit

h a

cti

ve d

isease.

Fig

5:

Po

st-

ch

em

oth

era

py P

ET

-CT

im

ag

ing

fo

r

lym

ph

om

a d

em

on

str

ate

s m

ult

ifo

cal

up

take i

n t

he

neck a

nd

axilla

e,

wh

ich

lo

calises t

o t

he n

orm

al

ap

peari

ng

fat

on

CT.

Th

is i

s i

n k

eep

ing

wit

h

ph

ysio

log

ical

bro

wn

fat

acti

vit

y a

nd

sh

ou

ld n

ot

be

co

nfu

sed

wit

h n

od

al

dis

ease.